Revvity (RVTY) Stock Analysis & AI Equity Report
Revvity (RVTY) overview
Revvity (RVTY) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 2,856m and operating profit of USD 357m; the year-end share price was 96.75 USD and market capitalisation was USD 10,863m. Revvity is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Revvity's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Revvity
Revvity provides health science products, technologies, expertise, and services spanning research, development, diagnosis, and healthcare. Its Life Sciences segment offers products, software, and services for cell, gene, and protein research and drug discovery and development workflows. Customers include pharmaceutical and biotechnology companies, contract research organizations, and academic and government institutions. The company also operates a Diagnostics segment.
Generate the Revvity report
Revvity is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Revvity and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Revvity
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.